glp-1 travel case Glp1 Storage Aesthetic – Sugar Medical Quantity:3-Bottles searchfilter_balance blood sugar GLP-1 Agonists Weight Loss

glp-1 travel case Glp1 Storage Aesthetic – Sugar Medical Quantity:3-Bottles searchfilter_balance blood sugar GLP-1 Agonists Weight Loss

GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis by Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030

doi: 10.1111/dom.12908

searchfilter_balance blood sugar

Quantity:3-Bottles

Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza®): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomach’s defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound®): Expanded approval for obesity 2023–2024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts